Plandai Biotechnology Return on Equity

Plandai Biotechnology (PLPL) currently reports a ROE of 1.06%. That is above the Healthcare sector average of 29.39%. Use the charts on this page to explore Plandai Biotechnology's ROE history and peer comparisons.

Plandai Biotechnology's ROE of 1.06% is higher than the Healthcare sector average of 29.39%. That is roughly 259.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Plandai Biotechnology's current 1.06% should be judged against Healthcare norms (sector average: 29.39%) and against PLPL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1.06%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Plandai Biotechnology, and consider following PLPL for alerts when major investors trade the stock.

Plandai Biotechnology is classified in the Healthcare sector. On ROE, it currently shows 1.06% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLPL with unrelated industries.